| scholarly article | Q13442814 |
| P2093 | author name string | Henderson D | |
| Ryffel GU | |||
| Cato AC | |||
| Klein-Hitpass L | |||
| P2860 | cites work | Two distinct estrogen-regulated promoters generate transcripts encoding the two functionally different human progesterone receptor forms A and B | Q24556548 |
| The steroid and thyroid hormone receptor superfamily | Q27861095 | ||
| The effects of an antiprogesterone steroid in women: interruption of the menstrual cycle and of early pregnancy | Q28274326 | ||
| Mechanisms of nuclear localization of the progesterone receptor: evidence for interaction between monomers | Q28276809 | ||
| Gene regulation by steroid hormones | Q29618291 | ||
| Inhibition of estrogen receptor-DNA binding by the "pure" antiestrogen ICI 164,384 appears to be mediated by impaired receptor dimerization | Q33777797 | ||
| The hormone regulatory element of mouse mammary tumour virus mediates progesterone induction | Q33880358 | ||
| Agonistic and antagonistic activities of RU486 on the functions of the human progesterone receptor | Q33923267 | ||
| The hormone response element of the mouse mammary tumour virus DNA mediates the progestin and androgen induction of transcription in the proviral long terminal repeat region. | Q33928807 | ||
| Contragestion and other clinical applications of RU 486, an antiprogesterone at the receptor | Q34544071 | ||
| Liver cell specific gene transcription in vitro: the promoter elements HP1 and TATA box are necessary and sufficient to generate a liver-specific promoter | Q35864691 | ||
| Antiprogestins, a new form of endocrine therapy for human breast cancer | Q36024326 | ||
| Repression of the alpha-fetoprotein gene promoter by progesterone and chimeric receptors in the presence of hormones and antihormones | Q36726228 | ||
| Specific binding of estrogen receptor to the estrogen response element | Q36752836 | ||
| Factors involved in specific transcription by human RNA polymerase II: analysis by a rapid and quantitative in vitro assay | Q37522721 | ||
| Regulation of gene expression by nuclear hormone receptors | Q38326537 | ||
| Progesterone receptor stimulates transcription of mouse mammary tumour virus in a cell-free system | Q38341540 | ||
| The progesterone receptor stimulates cell-free transcription by enhancing the formation of a stable preinitiation complex | Q38342253 | ||
| Steroid hormone-dependent interaction of human progesterone receptor with its target enhancer element | Q38345947 | ||
| Identification of a functional intermediate in receptor activation in progesterone-dependent cell-free transcription | Q41731206 | ||
| In situ photolinked nuclear progesterone receptors of human breast cancer cells: subunit molecular weights after transformation and translocation | Q44011636 | ||
| Antitumor activity of the antiprogestins ZK 98.299 and RU 38.486 in hormone dependent rat and mouse mammary tumors: mechanistic studies | Q45152380 | ||
| Reduced levels of hsp90 compromise steroid receptor action in vivo | Q45391521 | ||
| Differential gene activation by glucocorticoids and progestins through the hormone regulatory element of mouse mammary tumor virus | Q45841615 | ||
| Glucocorticoid and progesterone receptors bind to the same sites in two hormonally regulated promoters | Q48381314 | ||
| The antiprogestin RU38 486: receptor-mediated progestin versus antiprogestin actions screened in estrogen-insensitive T47Dco human breast cancer cells. | Q53845998 | ||
| Carcinogenesis: A superfamily of potentially oncogenic hormone receptors | Q59077092 | ||
| Receptors bound to antiprogestin form abortive complexes with hormone responsive elements | Q59081172 | ||
| Steroid hormone receptors compete for factors that mediate their enhancer function | Q61818663 | ||
| The estrogen receptor binds tightly to its responsive element as a ligand-induced homodimer | Q67927526 | ||
| Molecular interactions of steroid hormone receptor with its enhancer element: evidence for receptor dimer formation | Q67927534 | ||
| A high-efficiency HeLa cell nuclear transcription extract | Q68287469 | ||
| Interaction of the antioestrogen ICI 164,384 with the oestrogen receptor | Q68419252 | ||
| Studies on the mechanisms of action of progesterone antagonists | Q68930079 | ||
| A rapid method of epitope mapping. Application to the study of immunogenic domains and to the characterization of various forms of rabbit progesterone receptor | Q69039233 | ||
| Antitumor activity of the progesterone antagonists ZK 98.299 and RU 38.486 in the hormone-dependent MXT mammary tumor model of the mouse and the DMBA- and the MNU-induced mammary tumor models of the rat | Q69194540 | ||
| Cooperative binding of steroid hormone receptors contributes to transcriptional synergism at target enhancer elements | Q69369913 | ||
| The antitumor mechanism of progesterone antagonists is a receptor mediated antiproliferative effect by induction of terminal cell death | Q69449192 | ||
| Immunologic analysis of human breast cancer progesterone receptors. 1. Immunoaffinity purification of transformed receptors and production of monoclonal antibodies | Q69464715 | ||
| Viral enhancer activity in teratocarcinoma cells | Q70133049 | ||
| A secreted glycoprotein induced by estrogen in human breast cancer cell lines | Q71235918 | ||
| New steroids with antiprogestational and antiglucocorticoid activities | Q72602909 | ||
| P433 | issue | 6 | |
| P304 | page(s) | 1227-1234 | |
| P577 | publication date | 1991-03-01 | |
| P1433 | published in | Nucleic Acids Research | Q135122 |
| P1476 | title | Two types of antiprogestins identified by their differential action in transcriptionally active extracts from T47D cells | |
| P478 | volume | 19 |
| Q45868193 | A novel RU486 inducible system for the activation and repression of genes. |
| Q73141156 | Agonist and antagonist-induced qualitative and quantitative alterations of progesterone receptor from breast cancer cells |
| Q77415083 | Antiovulatory and postcoital antifertility activity of the antiprogestin CDB-2914 when administered as single, multiple, or continuous doses to rats |
| Q45974241 | Antiprogestin pharmacodynamics, pharmacokinetics, and metabolism: implications for their long-term use. |
| Q38340041 | Antiprogestins mediate differential effects on glucocorticoid receptor remodeling of chromatin structure |
| Q35909300 | Antiprogestins prevent progesterone receptor binding to hormone responsive elements in vivo |
| Q73830146 | Characterization of ligand binding, DNA binding and phosphorylation of progesterone receptor by two novel progesterone receptor antagonist ligands |
| Q28202581 | Coactivator/corepressor ratios modulate PR-mediated transcription by the selective receptor modulator RU486 |
| Q78017200 | Coregulatory proteins in nuclear hormone receptor action |
| Q28366589 | Demonstration of mixed properties of RU486 in progesterone receptor (PR)-transfected MDA-MB-231 cells: a model for studying the functions of progesterone analogues |
| Q40509133 | Differential DNA-binding abilites of estrogen receptor occupied with two classes of antiestrogens: studies using human estrogen receptor overexpressed in mammalian cells |
| Q34137268 | Genome-wide progesterone receptor binding: cell type-specific and shared mechanisms in T47D breast cancer cells and primary leiomyoma cells |
| Q95721243 | Hormone-induced nucleosome positioning in the MMTV promoter is reversible |
| Q36935311 | Hormone-induced progesterone receptor phosphorylation consists of sequential DNA-independent and DNA-dependent stages: analysis with zinc finger mutants and the progesterone antagonist ZK98299. |
| Q41038864 | Human progesterone receptor A and B isoforms in CHO cells. II. Comparison of binding, transactivation and ED50 values of several synthetic (anti)progestagens in vitro in CHO and MCF-7 cells and in vivo in rabbits and rats |
| Q41296506 | Identification of a Transactivation Function in the Progesterone Receptor That Interacts with the TAFII110 Subunit of the TFIID Complex |
| Q36298269 | In vivo evidence against the existence of antiprogestins disrupting receptor binding to DNA |
| Q42543741 | Interference between progesterone and dioxin signal transduction pathways. Different mechanisms are involved in repression by the progesterone receptor A and B isoforms |
| Q53559856 | Leukaemia inhibitory factor receptor and gp130 in the human Fallopian tube and endometrium before and after mifepristone treatment and in the human preimplantation embryo. |
| Q37337779 | Ligand-dependent conformational changes in the progesterone receptor are necessary for events that follow DNA binding |
| Q30847717 | Ligand-specific dynamics of the progesterone receptor in living cells and during chromatin remodeling in vitro |
| Q41584934 | Modulators of cellular protein phosphorylation alter the trans-activation function of human progesterone receptor and the biological activity of progesterone antagonists |
| Q38993290 | Molecular screening of Chinese medicinal plants for progestogenic and anti-progestogenic activity |
| Q36379145 | Nuclear progesterone receptor is mainly heat shock protein 90-free in vivo |
| Q33634265 | Partial agonist activity of the progesterone receptor antagonist RU486 mediated by an amino-terminal domain coactivator and phosphorylation of serine400 |
| Q57286101 | Phase I study of onapristone, a type I antiprogestin, in female patients with previously treated recurrent or metastatic progesterone receptor-expressing cancers |
| Q35161037 | Potential role of hCG in apoptosis of human luteinized granulosa cells |
| Q35547299 | Progesterone antagonists and progesterone receptor modulators |
| Q44395983 | Progesterone receptor isoform B in the human fallopian tube and endometrium following mifepristone |
| Q34282690 | Progesterone receptor transcription and non-transcription signaling mechanisms |
| Q28569643 | Progesterone-induced sphingosine kinase-1 expression in the rat uterus during pregnancy and signaling consequences |
| Q24657518 | Promotion of agonist activity of antiandrogens by the androgen receptor coactivator, ARA70, in human prostate cancer DU145 cells |
| Q53613549 | Prostaglandin E2 and F2alpha receptors in the human Fallopian tube before and after mifepristone treatment. |
| Q38199191 | Recent advances in structure of progestins and their binding to progesterone receptors |
| Q73327360 | Regulation of cell growth of a progestin-dependent murine mammary carcinoma in vitro: progesterone receptor involvement in serum or growth factor-induced cell proliferation |
| Q35234340 | Regulation of gene expression by steroid hormones |
| Q34594132 | Regulation of muscular contractions in the human Fallopian tube through prostaglandins and progestagens |
| Q82863309 | Selective effects of 8-Br-cAMP on agonists and antagonists of the glucocorticoid receptor |
| Q38319261 | Specific binding of progesterone receptor to progesterone‐responsive elements does not require prior dimerization |
| Q33694909 | Tamoxifen resistant breast cancer: coregulators determine the direction of transcription by antagonist-occupied steroid receptors |
| Q35193278 | The androgen receptor: structure, mutations, and antiandrogens |
| Q28263578 | The nuclear corepressors NCoR and SMRT are key regulators of both ligand- and 8-bromo-cyclic AMP-dependent transcriptional activity of the human progesterone receptor |
| Q36299014 | The progesterone antagonist RU486 acquires agonist activity upon stimulation of cAMP signaling pathways |
| Q33857422 | The selective progesterone receptor modulator CDB4124 inhibits proliferation and induces apoptosis in uterine leiomyoma cells |
| Q38325856 | Thyroid hormone alters the DNA binding properties of chicken thyroid hormone receptors alpha and beta |
| Q40852076 | Transcription activation by nuclear receptors |
| Q97640541 | Treating PMP22 gene duplication-related Charcot-Marie-Tooth disease: The past, the present and the future |
| Q42513872 | Two types of anti-progestins have distinct effects on site-specific phosphorylation of human progesterone receptor |
| Q43806911 | ZK98299—A new antiprogesterone: Biochemical characterization of steroid binding parameters in the calf uterine cytosol |
| Q35189958 | p300 and estrogen receptor cooperatively activate transcription via differential enhancement of initiation and reinitiation |
| Q42463636 | p53 suppresses cytokine induced, Stat5 mediated activation of transcription |
Search more.